# Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

> **NCT05270733** · PHASE4 · RECRUITING · sponsor: **University Hospitals Cleveland Medical Center** · enrollment: 56 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT05270733
- **Lead sponsor:** University Hospitals Cleveland Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05270733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05270733, "Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05270733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*